• 1
    Burke PJ, Karp JE, Braine HG, Vaughan WP. Timed sequential therapy of human leukemia based upon the response of leukemic cells to humoral growth factors. Cancer Res. 1977; 37: 2138-2146.
  • 2
    Karp JE, Donehower RC, Enterline JP, et al. In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia. Blood. 1989; 73: 24-30.
  • 3
    Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood. 1996; 87: 4979-4989.
  • 4
    Castaigne S, Chevret S, Archimbaud E, et al. Randomized comparison of double induction and timed-sequential induction to a “3 + 7” induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood. 2004; 104: 2467-2474.
  • 5
    Kalaycio M, Advani A, Pohlman B, et al. Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia. Am J Hematol. 2008; 83: 831-834.
  • 6
    Buchner T, Hiddemann W, Wormann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood. 1999; 93: 4116-4124.
  • 7
    Martino R, Guardia R, Altes A, Sureda A, Brunet S, Sierra J. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol. Haematologica. 1999; 84: 226-230.
  • 8
    Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors. Ann Hematol. 2003; 82: 684-690.
  • 9
    Archimbaud E, Thomas X, Leblond V, et al. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol. 1995; 13: 11-18.
  • 10
    Petersdorf SH, Rankin C, Head DR, et al. Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500). Am J Hematol. 2007; 82: 1056-1062.
  • 11
    Cassileth PA, Lee SJ, Litzow MR, et al. Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995). Leuk Lymphoma. 2005; 46: 55-61.
  • 12
    Capizzi RL, Davis R, Powell B, et al. Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia-a Cancer and Leukemia Group B Study. J Clin Oncol. 1988; 6: 499-508.
  • 13
    Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998; 92: 2322-2333.
  • 14
    Geller R, Burke P, Karp J, et al. A 2-step timed sequential treatment for acute myelocytic leukemia. Blood. 1989; 74: 1499-1506.
  • 15
    Braess J, Spiekermann K, Staib P, et al. Dose-dense induction with sequential high-dose cytarabine and mitoxantrone (S-HAM)and pegfilgrastim results in a high efficacy and short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood. 2009; 113: 3903-3910.
  • 16
    Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009; 361: 1249-1259.
  • 17
    Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: review of 3 randomized trials. Cancer. 2006; 107: 116-124.
  • 18
    Ravandi F, Issa JP, Garcia-Manero G, et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer. 2009; 115: 5746-5751.
  • 19
    Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005; 105: 54-60.
  • 20
    Ravandi F, Cortes J, Jones D, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010; 28: 1856-1862.